ProMIS Neurosciences Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
PMN$4.05-2.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Shareholders’ Equity
| · · · · · · · · · · · · · · · · · · · · · · · · · · · | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · · · · · · · · · · · Accumulated · · · · · · | ||||||||||||||||||||||
| · · Series 1 Convertible · · Series 2 Convertible · · · · · · · Additional · · Other · · · · · | ||||||||||||||||||||||
| · · Preferred Shares · · Preferred Shares · · Common Shares · · Paid-in · · Comprehensive · · Accumulated · · | ||||||||||||||||||||||
| · · Shares · · Amount · · Shares · · Amount · · Shares · · Amount · · Capital · · Income (Loss) · · Deficit · · Total | ||||||||||||||||||||||
| Balance, July 1, 2023 | 70,000,000 | $— | — | $— | 8,579,284 | $— | $79,367,762 | $(371,184) | $(87,524,869) | $(8,528,291) | ||||||||||||
| Proceeds from the issuance of common stock, pre-funded warrants and accompanying common warrants in August 2023 PIPE, net of issuance costs of $2,738,558 | | — | | — | — | | — | 9,945,970 | | — | | 17,745,200 | | — | | — | | | 17,745,200 | |||
| Reclassification of USD denominated warrants from warrant liability to additional paid-in capital due to change in functional currency | | — | | — | — | | — | — | | — | | 1,287,400 | | — | | — | | | 1,287,400 | |||
| Reclassification of CAD denominated warrants from additional paid-in capital to warrant liability due to change in functional currency | | — | | — | — | | — | — | | — | | (396,375) | | — | | — | | | (396,375) | |||
| Reclassification of CAD equity-classified stock options to share-based compensation liability due to change in functional currency | | — | | — | — | | — | — | | — | | (1,435,913) | | — | | — | | | (1,435,913) | |||
| Re-measurement of liability-classified CAD stock options as of September 30, 2023 | | — | | — | — | | — | — | | — | | | 443,516 | | — | | — | | | 443,516 | ||
| Net loss | — | | — | — | | — | — | | — | | — | | — | | (2,360,648) | | | (2,360,648) | ||||
| Balance, September 30, 2023 | 70,000,000 | | $— | | — | | $— | | 18,525,254 | | $— | $97,011,590 | $(371,184) | $(89,885,517) | | $6,754,889 | ||||||
| · · · · · · · · · · · · · · · · · · · · · · | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · · · · · · Accumulated · · · · · · | |||||||||||||||||||
| · · Series 2 Convertible · · · · · · · Additional · · Other · · · · · · | |||||||||||||||||||
| · · Preferred Shares · · Common Shares · · Paid-in · · Comprehensive · · Accumulated · · · | |||||||||||||||||||
| · · Shares · · Amount · · Shares · · Amount · · Capital · · Income (Loss) · · Deficit · · Total | |||||||||||||||||||
| Balance, July 1, 2024 | 1,166,667 | | $— | 18,961,116 | | $— | | $97,818,797 | | $(371,184) | | $(99,724,691) | | $(2,277,078) | |||||
| Share-based compensation expense | | — | | — | — | | — | | 121,036 | | | — | | | — | | | 121,036 | |
| Conversion of Series 2 Convertible Preferred Shares | | (1,166,667) | | — | 1,166,667 | | — | | — | | | — | | | — | | | — | |
| Issuance of Common Shares, pre-funded warrants and accompanying Common Share warrants in July 2024 PIPE, net of issuance costs of $2,645,487 | | — | | — | 9,757,669 | | — | | — | | | — | | | — | | | — | |
| Re-measurement of liability-classified CAD stock options as of September 30, 2024 | | — | | — | — | | — | | | 125,398 | | | — | | | — | | | 125,398 |
| Issuance of Common Shares from exercise of pre-funded warrants | | — | | — | 2,803,738 | | — | | | 28,039 | | | — | | | — | | | 28,039 |
| Net income | — | | — | — | | — | | — | | — | | 9,275,825 | | 9,275,825 | |||||
| Balance, September 30, 2024 | — | | $— | 32,689,190 | | $— | | $98,093,270 | | $(371,184) | | $(90,448,866) | | $7,273,220 | |||||
| · · · · · · · · · · · · · · · · · · · · · · · · · · · | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · · · · · · · · · · · Accumulated · · · · · · | ||||||||||||||||||||||||
| · · Series 1 Convertible · · Series 2 Convertible · · · · · · · Additional · · Other · · · · · | ||||||||||||||||||||||||
| · · Preferred Shares · · Preferred Shares · · Common Shares · · Paid-in · · Comprehensive · · Accumulated · · | ||||||||||||||||||||||||
| · · Shares · · Amount · · Shares · · Amount · · Shares · · Amount · · Capital · · Income (Loss) · · Deficit · · Total | ||||||||||||||||||||||||
| Balance, January 1, 2023 | 70,000,000 | $— | — | $— | 8,579,284 | | $— | $79,101,061 | $(195,369) | $(80,253,464) | $(1,347,772) | |||||||||||||
| Share-based compensation | — | | — | — | | — | — | | — | | 266,701 | | — | | — | | | 266,701 | ||||||
| Foreign currency translation | — | | — | — | | — | — | | — | | — | | (175,815) | | — | | | (175,815) | ||||||
| Proceeds from the issuance of common stock, pre-funded warrants and accompanying common warrants in August 2023 PIPE, net of issuance costs of $2,738,558 | | — | | — | — | | — | 9,945,970 | | — | | 17,745,200 | | — | | — | | | 17,745,200 | |||||
| Reclassification of USD denominated warrants from warrant liability to additional paid-in capital due to change in functional currency | | — | | — | — | | — | — | | — | | 1,287,400 | | — | | — | | | 1,287,400 | |||||
| Reclassification of CAD denominated warrants from additional paid-in capital to warrant liability due to change in functional currency | | — | | — | — | | — | — | | — | | (396,375) | | — | | — | | | (396,375) | |||||
| Reclassification of CAD equity-classified stock options to share-based compensation liability due to change in functional currency | | — | | — | — | | — | — | | — | | (1,435,913) | | — | | — | | | (1,435,913) | |||||
| Re-measurement of liability-classified CAD stock options as of September 30, 2023 | | — | | — | — | | — | — | | — | | | 443,516 | | — | | — | | | 443,516 | ||||
| Net loss | — | | | — | — | | | — | — | | — | | — | | — | | (9,632,053) | | | (9,632,053) | ||||
| Balance, September 30, 2023 | 70,000,000 | | $— | | — | | $— | | 18,525,254 | | $— | $97,011,590 | $(371,184) | $(89,885,517) | | $6,754,889 | ||||||||
| · · · · · · · · · · · · · · · · · · · · · · | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · · · · · · Accumulated · · · · · · | |||||||||||||||||||
| · · Series 2 Convertible · · · · · · · Additional · · Other · · · · · · | |||||||||||||||||||
| · · Preferred Shares · · Common Shares · · Paid-in · · Comprehensive · · Accumulated · · · | |||||||||||||||||||
| · · Shares · · Amount · · Shares · · Amount · · Capital · · Income (Loss) · · Deficit · · Total | |||||||||||||||||||
| Balance, January 1, 2024 | 1,166,667 | $— | 18,885,254 | $— | $97,590,426 | $(371,184) | $(93,465,946) | $3,753,296 | |||||||||||
| Share-based compensation expense | — | | — | — | | — | | 202,619 | | — | | — | | 202,619 | |||||
| Conversion of Series 2 Convertible Preferred Shares | | (1,166,667) | | — | 1,166,667 | | — | | — | | | — | | | — | | | — | |
| Issuance of Common Shares from ATM Offering, net of issuance costs | | — | | — | 75,862 | | — | | 190,274 | | | — | | | — | | | 190,274 | |
| Issuance of Common Shares, pre-funded warrants and accompanying Common Share warrants in July 2024 PIPE, net of issuance costs of $2,645,487 | | — | | — | 9,757,669 | | — | | — | | | — | | | — | | | — | |
| Re-measurement of liability-classified CAD stock options as of September 30, 2024 | | — | | — | — | | — | | | 81,912 | | | — | | | — | | | 81,912 |
| Issuance of Common Shares from exercise of pre-funded warrants | | — | | — | 2,803,738 | | — | | | 28,039 | | | — | | | — | | | 28,039 |
| Net income | — | | — | — | | — | | — | | — | | 3,017,080 | | 3,017,080 | |||||
| Balance, September 30, 2024 | — | | $— | 32,689,190 | | $— | | $98,093,270 | | $(371,184) | | $(90,448,866) | | $7,273,220 | |||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.